158 related articles for article (PubMed ID: 38145398)
41. High grade infiltrative adenocarcinomas of renal cell origin: New insights into classification, morphology, and molecular pathogenesis.
Singh JA; Ohe C; Smith SC
Pathol Int; 2018 May; 68(5):265-277. PubMed ID: 29665139
[TBL] [Abstract][Full Text] [Related]
42. ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
Doğan K; Onder E
Pathol Res Pract; 2024 Jan; 253():154951. PubMed ID: 38039739
[TBL] [Abstract][Full Text] [Related]
43. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
[TBL] [Abstract][Full Text] [Related]
44. [FH (Fumarate Hydratase)-deficient renal cell carcinoma: A case report].
Allaume P; Kammerer-Jacquet SF; Papadopoulos S; Rioux-Leclercq N
Ann Pathol; 2023 Sep; 43(5):417-420. PubMed ID: 36822902
[TBL] [Abstract][Full Text] [Related]
45. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
[TBL] [Abstract][Full Text] [Related]
46. [SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts].
Agaimy A; Hartmann A
Pathologe; 2021 Nov; 42(6):571-577. PubMed ID: 34609565
[TBL] [Abstract][Full Text] [Related]
47. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.
Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y
Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946
[TBL] [Abstract][Full Text] [Related]
48. Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study.
Nikolovski I; Carlo MI; Chen YB; Vargas HA
Cancer Imaging; 2021 Feb; 21(1):24. PubMed ID: 33608050
[TBL] [Abstract][Full Text] [Related]
49. Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinoma.
Mannan R; Wang X; Bawa PS; Chugh S; Chinnaiyan AK; Rangaswamy R; Zhang Y; Cao X; Smith SC; Trpkov K; Williamson SR; Sangoi AR; Mohanty S; McKenney JK; Gupta S; Magi-Galluzzi C; Argani P; Osunkoya AO; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Hum Pathol; 2023 Apr; 134():102-113. PubMed ID: 36581128
[TBL] [Abstract][Full Text] [Related]
50. Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients.
Li Y; Reuter VE; Matoso A; Netto GJ; Epstein JI; Argani P
Histopathology; 2018 Mar; 72(4):588-600. PubMed ID: 28898443
[TBL] [Abstract][Full Text] [Related]
51. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
52. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes.
Gatalica Z; Lilleberg SL; Monzon FA; Koul MS; Bridge JA; Knezetic J; Legendre B; Sharma P; McCue PA
Hum Pathol; 2011 Dec; 42(12):1979-88. PubMed ID: 21733559
[TBL] [Abstract][Full Text] [Related]
53. Reporting on FH-deficient renal cell carcinoma using circulating succinylated metabolites.
Bezwada D; Brugarolas J
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37259915
[TBL] [Abstract][Full Text] [Related]
54. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.
Williamson SR; Gill AJ; Argani P; Chen YB; Egevad L; Kristiansen G; Grignon DJ; Hes O
Am J Surg Pathol; 2020 Jul; 44(7):e47-e65. PubMed ID: 32251007
[TBL] [Abstract][Full Text] [Related]
55. Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification.
Udager AM; Mehra R
Arch Pathol Lab Med; 2016 Oct; 140(10):1026-37. PubMed ID: 27684973
[TBL] [Abstract][Full Text] [Related]
56. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
Halefoglu AM; Ozagari AA
Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
[TBL] [Abstract][Full Text] [Related]
57. Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.
Kwon R; Argani P; Epstein JI; Lombardo KA; Wang X; Pierorazio PM; Mehra R; Matoso A
Am J Surg Pathol; 2021 Apr; 45(4):450-462. PubMed ID: 33239504
[TBL] [Abstract][Full Text] [Related]
58. Kidney Tumors: New and Emerging Kidney Tumor Entities.
Siadat F; Mansoor M; Hes O; Trpkov K
Clin Lab Med; 2023 Jun; 43(2):275-298. PubMed ID: 37169446
[TBL] [Abstract][Full Text] [Related]
59. Kidney Tumors: New and Emerging Kidney Tumor Entities.
Siadat F; Mansoor M; Hes O; Trpkov K
Surg Pathol Clin; 2022 Dec; 15(4):713-728. PubMed ID: 36344185
[TBL] [Abstract][Full Text] [Related]
60. Exploration of clinicopathological features of rearranged renal cell carcinoma and TFE3, TFEB, and ALK staining performance in renal entities.
Liu Y; Li X; Fan Y; Xu H; Gu Y; Dong L; Zhou L; Yang X; Wang C
Heliyon; 2023 Apr; 9(4):e15159. PubMed ID: 37089387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]